2021
Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell CarcinomaClinical Implications of WES in Penile Squamous Carcinoma
Chahoud J, Gleber-Netto FO, McCormick BZ, Rao P, Lu X, Guo M, Morgan MB, Chu RA, Martinez-Ferrer M, Eterovic AK, Pickering CR, Pettaway CA. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell CarcinomaClinical Implications of WES in Penile Squamous Carcinoma. Clinical Cancer Research 2021, 27: 2560-2570. PMID: 33441293, DOI: 10.1158/1078-0432.ccr-20-4004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesComputational BiologyDisease ManagementDisease SusceptibilityExome SequencingHumansMaleMiddle AgedMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPenile NeoplasmsPrognosisSquamous Cell Carcinoma of Head and NeckConceptsPenile squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papilloma virus testingNeck squamous cell carcinomaNotch pathway alterationsMutation signaturesTumor mutation burdenWorse overall survivalLimited treatment optionsWhole-exome sequencing analysisPenile squamous carcinomaPotential clinical implicationsMutational signaturesDefective DNA mismatch repairCancer Genome Atlas studyWhole-exome sequencingNovel druggable targetsDistinct mutational signaturesNormal penile tissuesOverall survivalWorse survivalHigh TMBSquamous carcinomaPenile tissue
2019
Genetics and penile cancer: recent developments and implications.
Chahoud J, Pickering CR, Pettaway CA. Genetics and penile cancer: recent developments and implications. Current Opinion In Urology 2019, 29: 364-370. PMID: 31045928, DOI: 10.1097/mou.0000000000000640.Peer-Reviewed Original ResearchConceptsPenile squamous cell carcinomaSquamous cell carcinomaCell carcinomaGene alterationsMultiple squamous cell carcinomasSimilar tumour mutational burdenRecurrent gene alterationsTargetable gene alterationsPD-1 inhibitionOngoing clinical trialsTumor mutational burdenTumor suppressor gene alterationsDifferent organ sitesPenile cancerHuman papillomavirusRare tumorClinical trialsNovel agentsLarge cohortMutational burdenTrial designOrgan sitesPSCC casesPositive expressionRNA signature